ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 70 effective May 31, 2019 (the “Effective Date”). The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market.
Shares of the nano-cap, thinly traded biotech ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) were trading nearly 150-percent higher Thursday. What Happened ContraVir, which focuses on therapies for liver ...
ContraVir Pharmaceuticals (NASDAQ:CTRV) had a memorable Friday as the company's stock soared off the heels of a successful results regarding one of its treatments for liver disease.Source: Shutterstock The Edison, New Jersey-based pharmaceutical business today unveiled findings from a preclinical study in which CRV431, which is a novel cyclophilin inhibitor, significantly helped to decrease the extent of fibrosis in a second animal model of liver fibrosis. The term fibrosis refers to scarring of the liver, and it is a common symptom of non-alcoholic steatohepatitis (NASH), which causes impaired liver function.ContraVir Pharmaceuticals focuses mostly on developing therapeutic drugs to treat liver disease that arises from NASH. The company said that obeticholic acid (OCA), which is a semi-synthetic bile acid analogue drug, was approved for the treatment of primary biliary cholangitis (PBC), and it is being evaluated in Phase 3 trials by another company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe medication was used by a comparator drug within the study and did not decrease the extent of fibrosis in this study conducted by the company. This industry-standard model requires liver fibrosis to be induced in mice by administering carbon tetrachloride."This is the second animal model, and the fifth study overall, in which CRV431 consistently demonstrated a statistically significant reduction in fibrosis," said Dr. Robert Foster, Chief Executive Officer of ContraVir. "In addition, this study showed that CRV431 reduced fibrosis where OCA, a drug approved for PBC with potential to treat additional liver diseases, such as NASH, did not." More From InvestorPlace * 10 Stocks to Buy That Could Be Takeover Targets * 7 S&P 500 Stocks to Buy That Tore Up Earnings * The 10 Best Stocks for 2019 -- So Far Compare Brokers The post Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today appeared first on InvestorPlace.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that the U.S. Food and Drug Administration (“FDA”) has reviewed its Investigational New Drug (“IND”) application for CRV431 for the treatment of NASH and has authorized that the Company proceed with its planned IND opening study. This IND for NASH is in addition to the Company’s current open IND for hepatitis B virus (“HBV”).
EDISON, N.J., June 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.
The loss of momentum is unfortunate, but not devastating. Part of making a career of day trading is understanding that swings in momentum like this happen, and traders need to be prepared for dry spells. The first step in finding balance while momentum disappears is recognizing when reliable trading setups become less reliable.
ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced the pricing of a public offering with expected total gross proceeds of approximately $15.6 million, before deducting placement agent fees and other offering expenses payable by the Company. Roth Capital Partners is acting as the lead placement agent for the offering. Arcadia Securities, LLC is acting as co-placement agent for the offering.
ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from a preclinical study where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of fibrosis in a second animal model of liver fibrosis. Fibrosis, or scarring, of the liver is a hallmark symptom of NASH that results in impaired liver function.
ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) shares have been highly volatile of late, with the promise offered by its non-alcoholic steatohepatitis drug cushioning any downside for the stock. ContraVir, a thinly traded nanocap biotech, said Thursday after the close the FDA has given it positive feedback in response to its pre-IND meeting about its NASH pipeline asset CRV431. The positive feedback pertained to preclinical data for CRV431, with the regulatory body agreeing with ContraVir's proposed plan for further preclinical studies to support the development of the asset.
ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from its first study with human precision cut liver slice cultures. Liver disease was simulated in this unique experimental model by application of the potent, profibrotic molecules, TGFβ and PDGF.
ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following ...
ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that its Board of Directors has approved the change of the Company’s name and stock symbol to Hepion Pharmaceuticals, Inc. and “HEPA,” respectively. The Company’s new NASDAQ trading symbol will be effective as of the opening of trading on July 23, 2019, as will a new CUSIP number for the Company’s common stock of 426897104. “We derived the name ‘Hepion’ by combining the ancient Greek word for liver, ‘hepar,’ with ‘Epione,’ the goddess of soothing, or healing,” commented Dr. Robert Foster, the Company’s CEO.
Investors love a turnaround play, and Wall Street is littered with stories of fortunes made betting on troubled companies.In the 1960s, American Express (AXP) was rumored to be near bankruptcy when Warren Buffett famously entered what is now one of his favorite Berkshire Hathaway positions. Apple (AAPL), which became the first U.S. company to hit $1 trillion in market value, absorbed more than a decade of losses during the 1980s and '90s before Steve Jobs helped turn the company around - aided by a $150 million investment from Microsoft (MSFT).But while every beat-up stock is a potential turnaround play, not every company achieves that potential. And losses can mount quickly for a stock that's already up against the ropes. So while you might be tempted to dabble in a potential comeback story or two, beware of some of the most common traps that end in disaster.Sometimes the issue is too much debt; rising interest costs and balloon payments can turn minor business setbacks into major liquidity challenges. Other times, once-powerful consumer brands are brought to their knees by management that's too slow to adapt to evolving consumer tastes.Certain areas of the market can be particularly prone to disasters. Start-up biotech stocks are risky because they're racing against the clock to bring new drugs to market before their cash runs out. Disappointing clinical trial result, in these cases, can cut a stock's value in half (or worse) within days. Chinese stocks are problematic, too, because of sometimes poor visibility and weak corporate governance.Here are 13 stocks to sell if you own them, or avoid if you're on the hunt for the next turnaround story. The companies themselves aren't necessarily an extinction threat, but for varying reasons, they're all on the brink of delivering more disastrous returns. SEE ALSO: Beware the Risks in These 13 Blue-Chip Stocks
ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced the filing of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for CRV431 for the treatment of NASH.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...